ARAY Stock Risk & Deep Value Analysis
Accuray Inc
DVR Score
out of 10
What You Need to Know About ARAY Stock
We analyzed Accuray Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ARAY through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
ARAY Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is the failure to resolve the Nasdaq non-compliance notice, which could lead to delisting and severely impair liquidity and investor confidence. This, combined with persistent operating losses, high debt, and potential highly dilutive financing, could push the company towards bankruptcy or render existing shares almost worthless.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
Medium
Red Flags
- ⚠
Nasdaq non-compliance notice for minimum bid price rule (< $1 for 30 days)
- ⚠
Sustained net losses ($13.8M in Q2 2026) and declining revenue YoY
- ⚠
High debt-to-equity ratio (254.4%) and significant net debt ($94.6M)
- ⚠
BTIG analyst price target cut from $4 to $2 following Q2 earnings
- ⚠
Low gross margin (23.5%) for a specialized medical device company
Upcoming Risk Events
- 📅
Failure to regain Nasdaq compliance leading to delisting
- 📅
Continued year-over-year revenue decline in Q3/Q4 2026
- 📅
Further deterioration of gross margins or increasing cash burn
When to Reconsider
- 🚪
Formal delisting from Nasdaq or transfer to OTC market
- 🚪
Quarterly revenue drops below $90M for two consecutive quarters
- 🚪
Cash balance falls below $20M without clear, non-dilutive financing
- 🚪
Debt-to-equity ratio exceeds 3.0
Unlock ARAY Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Accuray is a deeply undervalued, highly speculative play on a potential turnaround or acquisition within the specialized radiation oncology market. Its niche CyberKnife and TomoTherapy systems hold valuable IP, but the company is currently plagued by precarious financials, execution challenges, and a critical Nasdaq delisting threat. Investment hinges on a swift resolution of the Nasdaq issue and unexpected stabilization or growth in future quarters, ideally leading to a strategic takeover.
Is ARAY Stock Undervalued?
Unlock the full AI analysis for ARAY
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
ARAY Price Targets & Strategy
12-Month Target
$1.80
Bull Case
$2.50
Bear Case
$0.10
Valuation Basis
Based on 0.7x EV/Sales on estimated FY26 revenue of $445M, implying an Enterprise Value of $311.5M, less net debt of $94.6M, divided by 118.78M shares outstanding.
Entry Strategy
Dollar-cost average at current levels ($0.40-$0.50), acknowledging extreme risk. Monitor for clear signs of Nasdaq compliance resolution.
Exit Strategy
Take 50% profit at $1.50, remaining at $2.50. Implement a strict stop-loss at $0.25 to manage downside risk given delisting threats.
Portfolio Allocation
0.5% for highly aggressive, speculative portfolios only.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is ARAY Financially Healthy?
Profitability
Gross Margin
27.83%
Operating Margin
-3.69%
Net Margin
-8.15%
Return on Equity
-57.91%
Revenue Growth
-3.57%
EPS
$-0.30
Balance Sheet
Current Ratio
1.65
Quick Ratio
0.85
Debt/Equity
1.68
Total Debt
$135.90M
Cash & Equivalents
$41.30M
Other
Beta (Volatility)
1.36
Does ARAY Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Eroding
Moat Sources
2 Identified
While Accuray possesses valuable intellectual property in precision radiation delivery and its installed base faces high switching costs, the financial instability and lack of substantial R&D investment limit its ability to maintain and expand this moat against well-capitalized competitors. The moat is becoming less durable as financial health deteriorates.
Moat Erosion Risks
- •Competitors developing superior or more cost-effective technologies
- •Inability to fund necessary R&D to maintain technological leadership
- •Loss of market credibility due to financial distress and Nasdaq issues
ARAY Competitive Moat Analysis
Sign up to see competitive advantages
ARAY Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bearish, reflecting the low stock price and delisting concerns.
Institutional Sentiment
Negative, evidenced by BTIG's significant price target cut, despite maintaining a 'Buy' rating. Overall analyst coverage is low.
Insider Activity (Form 4)
On April 1, 2026, an amended consulting agreement with Dedication Capital (an affiliate of director Steven F. Mayer) cut base fees by 50% and modified equity vesting terms, suggesting cost-saving measures rather than strong insider conviction to buy.
Options Flow
Normal options activity; no specific unusual put/call ratio or large block trades were reported, likely due to its micro-cap status and low liquidity.
Earnings Intelligence
Next Earnings
2026-05-06
Surprise Probability
Low, given the Q2 2026 revenue miss and ongoing operational challenges.
Historical Earnings Pattern
Given recent performance, the stock is likely to react negatively to any further revenue misses or weak guidance, and positively only to unexpected strong turnaround signals or positive news regarding Nasdaq compliance.
Key Metrics to Watch
Competitive Position
Top Competitor
Elekta (EKTA-B.ST), Siemens Healthineers (SHL.DE) (Varian Medical Systems)
Market Share Trend
Likely stable to slightly losing, given the revenue decline in Q2 2026 and intense competition from larger, better-resourced players.
Valuation vs Peers
Accuray trades at a steep discount to profitable peers on EV/Sales (approx. 0.38x vs. typically 2-5x for healthy med-tech companies), reflecting its distressed financial state.
Competitive Advantages
- •Proprietary, highly specialized radiation therapy technology (CyberKnife, TomoTherapy)
- •Established installed base and associated service revenue stream
- •High switching costs for existing customers due to system complexity and capital investment
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive ARAY Stock Higher?
Near-Term (0-6 months)
- •Q3 2026 Earnings Report (May 6, 2026)
- •Resolution of Nasdaq minimum bid price non-compliance
Medium-Term (6-18 months)
- •Stabilization and return to modest revenue growth
- •Strategic partnership or licensing agreement for technology
Long-Term (18+ months)
- •Acquisition by a larger medical device company
- •Sustained profitability and market share gains in specialized oncology
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ARAY?
- ✓
Successful resolution of the Nasdaq minimum bid price compliance
- ✓
Reported return to positive year-over-year revenue growth
- ✓
Sustainable improvement in gross and operating margins
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Accuray Inc Makes Money
Accuray Inc. designs, develops, and sells advanced radiation therapy systems used for treating cancer and other medical conditions. Their two primary product lines are the CyberKnife and TomoTherapy systems, which deliver highly precise radiation to tumors. The company generates revenue by selling these high-capital medical devices to hospitals and cancer treatment centers globally. Additionally, a significant portion of its revenue comes from recurring service contracts, maintenance agreements, software upgrades, and parts sales for its installed base of systems.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Accuray Inc (ARAY)?
As of April 23, 2026, Accuray Inc has a DVR Score of 0.7 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Accuray Inc?
Accuray Inc's market capitalization is approximately $52.3M..
What is the risk level for ARAY stock?
Our analysis rates Accuray Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Accuray Inc's revenue growing?
Accuray Inc has reported revenue growth of -3.6%. Revenue has been declining, which warrants closer examination.
Is ARAY stock profitable?
Accuray Inc has a profit margin of -8.2%. The company is currently unprofitable.
How often is the ARAY DVR analysis updated?
Our AI-powered analysis of Accuray Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 23, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ARAY (Accuray Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.